Strong beat and raised guidance confirm accelerating organic growth and operating leverage. Upcoming Prosigna LDT and TrueMRD launches could extend the growth trajectory. Expect positive price action at open; watch for sell-side estimate upgrades and potential analyst day catalysts.
Price Chart
Executive Summary
Veracyte reported Q1 2026 earnings with total revenue of $139.1M (+21% YoY) and GAAP diluted EPS of $0.35, significantly beating Street consensus of $0.23. The company raised full-year 2026 total revenue guidance to $582M-$592M (from $570M-$582M) and adjusted EBITDA margin to >26% (from ~25%), driven by strong Decipher and Afirma testing volume growth.
Key Financial Metrics
Key Facts
- Total revenue $139.1M, +21% YoY
- Testing revenue $135.1M, +26% YoY
- GAAP diluted EPS $0.35 vs Street consensus $0.23 (52% beat)
- Decipher revenue +30% to $86.5M, Afirma revenue +21% to $46.4M
- Raised 2026 total revenue guidance to $582M-$592M (13-14% growth)
- Raised 2026 adjusted EBITDA margin guidance to >26%
- Adjusted EBITDA $42.8M (30.8% margin), +73% YoY
- Operating cash flow $35.2M, FCF $32.3M
- Cash & investments $439.1M at quarter end
Financial Impact
EPS beat of $0.12 (+52%) and guidance raise of $12M at midpoint
Risk Factors
- Execution risk on new product launches (Prosigna LDT, TrueMRD)
- Reimbursement changes for molecular diagnostic tests
- Dependence on Decipher and Afirma growth sustainability
- Biopharmaceutical revenue decline due to Veracyte SAS restructuring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001384101-26-000029 |
| Document: vcyt-20260505.htm | 0001384101-26-000029 |
| Document: 0001384101-26-000029-index-headers.html | 0001384101-26-000029 |
| Document: 0001384101-26-000029-index.html | 0001384101-26-000029 |
| Document: 0001384101-26-000029.txt | 0001384101-26-000029 |
| 8-K Data (Synthetic) | 0001384101-26-000029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | Press Release | $40.14 $43.36 | ▲ +8.02% | ▲ +5.89% | $45.61 (+13.63%) |
Sep 4, 2026 27d ago | Insider Cluster | $42.45 $40.14 | ▼ −5.44% | ▼ −4.32% | $45.61 (+7.44%) |
Jun 18, 2026 15w ago | 144 | $53.19 $60.49 | ▲ +13.72% | ▲ +15.79% | $45.61 (−14.25%) |
Jun 11, 2026 16w ago | Institutional Cluster | $47.33 $53.63 | ▲ +13.31% | ▲ +12.64% | $45.61 (−3.63%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▲ +2.87% | ▲ +3.44% | $45.61 (+6.40%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▼ −2.87% | ▼ −3.44% | $45.61 (−6.40%) |
May 27, 2026 18w ago | Insider Cluster | $47.99 $49.94 | ▲ +4.06% | ▲ +3.75% | $45.61 (−4.96%) |
May 20, 2026 19w ago | 144 | $45.19 $47.99 | ▲ +6.20% | ▲ +4.60% | $45.61 (+0.93%) |
May 5, 2026 21w ago | 8-K | $41.19 $39.56 | ▼ −3.96% | ▼ −5.09% | $45.61 (+10.73%) |
Apr 22, 2026 23w ago | DEFA14A | $33.15 $31.78 | ▼ −4.13% | ▼ −5.61% | $45.61 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access